Bayer ROE 2012-2025 | BAYRY
Current and historical return on equity (ROE) values for Bayer (BAYRY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Bayer ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-12-31 | $-4.10B | $33.29B | -12.31% |
| 2025-09-30 | $1.72B | $34.59B | 4.96% |
| 2025-06-30 | $-1.76B | $34.34B | -5.12% |
| 2025-03-31 | $-3.57B | $35.34B | -10.09% |
| 2024-12-31 | $-2.76B | $36.47B | -7.57% |
| 2024-09-30 | $-2.95B | $36.75B | -8.03% |
| 2024-06-30 | $-3.32B | $37.44B | -8.88% |
| 2024-03-31 | $-3.35B | $37.91B | -8.84% |
| 2023-12-31 | $-3.18B | $39.21B | -8.12% |
| 2023-09-30 | $-4.25B | $40.51B | -10.48% |
| 2023-06-30 | $1.28B | $41.82B | 3.05% |
| 2023-03-31 | $3.02B | $41.87B | 7.21% |
| 2022-12-31 | $4.37B | $41.41B | 10.56% |
| 2022-09-30 | $5.30B | $40.97B | 12.93% |
| 2022-06-30 | $4.85B | $39.75B | 12.19% |
| 2022-03-31 | $2.36B | $38.79B | 6.08% |
| 2021-12-31 | $1.18B | $38.72B | 3.05% |
| 2021-09-30 | $-0.10B | $37.68B | -0.26% |
| 2021-06-30 | $-3.41B | $37.66B | -9.04% |
| 2021-03-31 | $-11.11B | $38.32B | -29.00% |
| 2020-12-31 | $-11.99B | $41.29B | -29.03% |
| 2020-09-30 | $-10.51B | $45.83B | -22.94% |
| 2020-06-30 | $-6.15B | $49.46B | -12.44% |
| 2020-03-31 | $4.82B | $52.22B | 9.22% |
| 2019-12-31 | $4.58B | $52.42B | 8.74% |
| 2019-09-30 | $-1.69B | $52.74B | -3.21% |
| 2019-06-30 | $0.51B | $54.56B | 0.94% |
| 2019-03-31 | $1.01B | $56.01B | 1.80% |
| 2018-12-31 | $2.00B | $54.15B | 3.70% |
| 2018-09-30 | $7.49B | $50.95B | 14.69% |
| 2018-06-30 | $8.69B | $43.57B | 19.94% |
| 2018-03-31 | $9.08B | $39.25B | 23.14% |
| 2017-12-31 | $8.29B | $34.06B | 24.34% |
| 2017-09-30 | $7.98B | $32.47B | 24.58% |
| 2017-06-30 | $4.75B | $32.10B | 14.78% |
| 2017-03-31 | $4.96B | $29.13B | 17.02% |
| 2016-12-31 | $5.02B | $29.36B | 17.08% |
| 2016-09-30 | $5.26B | $27.60B | 19.05% |
| 2016-06-30 | $5.04B | $26.96B | 18.71% |
| 2016-03-31 | $4.76B | $26.38B | 18.04% |
| 2015-12-31 | $4.56B | $25.72B | 17.74% |
| 2015-09-30 | $4.06B | $25.37B | 15.99% |
| 2015-06-30 | $4.04B | $25.82B | 15.65% |
| 2015-03-31 | $4.08B | $26.32B | 15.48% |
| 2014-12-31 | $4.55B | $27.38B | 16.63% |
| 2014-09-30 | $4.99B | $27.57B | 18.09% |
| 2014-06-30 | $4.86B | $27.51B | 17.67% |
| 2014-03-31 | $4.65B | $27.17B | 17.12% |
| 2013-12-31 | $4.24B | $26.48B | 16.00% |
| 2013-09-30 | $4.08B | $25.54B | 15.96% |
| 2013-06-30 | $3.77B | $24.72B | 15.23% |
| 2013-03-31 | $3.30B | $24.32B | 13.58% |
| 2012-12-31 | $3.15B | $24.36B | 12.92% |
| 2012-09-30 | $3.21B | $25.10B | 12.78% |
| 2012-06-30 | $3.46B | $25.98B | 13.30% |
| 2012-03-31 | $3.90B | $26.82B | 14.52% |
| 2011-12-31 | $3.45B | $26.96B | 12.81% |
| 2011-09-30 | $2.72B | $26.52B | 10.25% |
| 2011-06-30 | $2.17B | $25.73B | 8.44% |
| 2011-03-31 | $1.77B | $24.99B | 7.07% |
| 2010-12-31 | $1.75B | $25.07B | 6.97% |
| 2010-09-30 | $2.16B | $25.40B | 8.52% |
| 2010-06-30 | $2.18B | $25.99B | 8.37% |
| 2010-03-31 | $2.23B | $26.23B | 8.51% |
| 2009-12-31 | $1.87B | $25.02B | 7.49% |
| 2009-09-30 | $1.79B | $24.42B | 7.32% |
| 2009-06-30 | $1.83B | $24.80B | 7.39% |
| 2009-03-31 | $2.02B | $25.30B | 7.97% |
| 2008-12-31 | $2.60B | $26.31B | 9.89% |
| 2008-09-30 | $2.74B | $26.06B | 10.51% |
| 2008-06-30 | $3.94B | $25.01B | 15.74% |
| 2008-03-31 | $3.92B | $23.68B | 16.54% |
| 2007-12-31 | $6.46B | $22.30B | 28.96% |
| 2007-09-30 | $6.60B | $20.57B | 32.10% |
| 2007-06-30 | $5.40B | $18.92B | 28.51% |
| 2007-03-31 | $5.08B | $17.47B | 29.05% |
| 2006-12-31 | $2.11B | $15.90B | 13.30% |
| 2006-09-30 | $1.72B | $15.34B | 11.19% |
| 2006-06-30 | $1.91B | $14.55B | 13.16% |
| 2006-03-31 | $1.86B | $13.86B | 13.45% |
| 2005-12-31 | $1.99B | $13.70B | 14.49% |
| 2005-09-30 | $2.02B | $14.08B | 14.34% |
| 2005-06-30 | $1.46B | $14.51B | 10.04% |
| 2005-03-31 | $1.09B | $14.97B | 7.28% |
| 2004-12-31 | $0.75B | $15.38B | 4.87% |
| 2004-09-30 | $-1.63B | $15.38B | -10.59% |
| 2004-06-30 | $-1.81B | $15.69B | -11.54% |
| 2004-03-31 | $-1.82B | $16.19B | -11.23% |
| 2003-12-31 | $-1.69B | $16.32B | -10.33% |
| 2003-09-30 | $0.23B | $16.50B | 1.38% |
| 2003-06-30 | $1.01B | $16.32B | 6.20% |
| 2003-03-31 | $1.14B | $15.62B | 7.27% |
| 2002-12-31 | $0.96B | $15.26B | 6.30% |
| 2002-09-30 | $1.50B | $14.99B | 10.01% |
| 2002-06-30 | $0.69B | $14.66B | 4.72% |
| 2002-03-31 | $0.92B | $14.84B | 6.18% |
| 2001-12-31 | $0.87B | $14.96B | 5.79% |
| 2001-09-30 | $0.96B | $14.98B | 6.39% |
| 2001-06-30 | $1.60B | $15.08B | 10.63% |
| 2001-03-31 | $1.56B | $14.89B | 10.45% |
| 2000-12-31 | $1.70B | $14.82B | 11.44% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |